Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan — Insights From the PARACLETE Study.
Many Japanese patients with heart failure have weight gain that might respond to newer diabetes drugs, expanding treatment possibilities.
The PARACLETE registry study characterized the prevalence of HFpEF patients in Japan who meet obesity-related eligibility criteria for incretin receptor agonists (GLP-1/GIP), identifying a real-world target population. This informs the potential scale of incretin-based therapy application in HFpEF management in Japan.
What the study was
- Study design
- Cross-sectional observational study (PARACLETE Study registry)
- Population
- Heart failure with preserved ejection fraction (HFpEF) patients in Japan, screened for obesity-related eligibility criteria for incretin receptor agonists
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Circulation Journal
Why it surfaced
Real-world epidemiology of HFpEF/obesity/incretin RA eligibility in Japan; informative for cardiometabolic treatment planning.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.